Anti-C1orf103/LRIF1 Antibody Picoband®

Predicted to enable nuclear retinoic acid receptor binding activity. Involved in dosage compensation by inactivation of X chromosome. Located in centriolar satellite; chromosome, telomeric region; and nuclear lumen. Implicated in facioscapulohumeral muscular dystrophy 3.

LRIF1; C1orf103; RIF1; Ligand-dependent nuclear receptor-interacting factor 1; HP1-binding protein enriched in inactive X chromosome protein 1; HBiX1; Receptor-interacting factor 1

E.coli-derived human C1orf103/LRIF1 recombinant protein (Position: Q157-D528) . Human C1orf103/LRIF1 shares 69% and 63.1% amino acid (aa) sequence identity with mouse and rat C1orf103/LRIF1, respectively.

1. Hamanaka, K., Sikrova, D., Mitsuhashi, S., Masuda, H., Sekiguchi, Y., Sugiyama, A., Shibuya, K., Lemmers, R. J. L. F., Goossens, R., Ogawa, M., Nagao, K., Obuse, C., Noguchi, S, Hayashi, Y. K., Kuwabara, S., Balog, J., Nishino, I., van der Maarel, S. M. Homozygous nonsense variant in LRIF1 associated with facioscapulohumeral muscular dystrophy. Neurology 94: e2441-e2447, 2020. 2. Li, H. J., Haque, Z. K., Chen, A., Mendelsohn, M. RIF-1, a novel nuclear receptor corepressor that associates with the nuclear matrix. J. Cell. Biochem. 102: 1021-1035, 2007.

At -20°C for one year from date of receipt. After reconstitution, at 4°C for one month. It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freezing and thawing.